EP300 and hepatocellular carcinoma: And both the RNA and protein levels of YTHDF2 in HCC cells were significantly downregulated after treatment with an H3K4me3 inhibitor (OICR‐9429) and an H3K27ac inhibitor (CBP/p300‐IN‐12) (Figure 1H).[29, 30] Taken together, these results demonstrated that the enrichment of H3K4me3 and H3K27ac in the promoter region might account for the upregulation of YTHDF2 in HCC, and higher expression of YTHDF2 predicted poorer prognosis.